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Abstract
Background: Triple negative breast cancers (TNBC) are a more aggressive subset of breast cancer. A better
understanding of its biology could allow the rational development of targeted therapies.
Methods: We extensively analyzed the EGFR/PI3K/PTEN axis in a large, homogeneous population of TNBC to help
defining the putative role of anti-EGFR and -PI3K targeted therapies in this setting. EGFR gene amplification, EGFR
protein expression, PIK3CA and PTEN gene alterations (two members of EGFR downstream pathways) and their
clinicopathological and prognostic implications were analyzed in 204 TNBC samples from European patients.
Results: EGFR amplification was detected in 18 of the 204 TNBC specimens (8.9 %) and was significantly associated with
higher EGFR protein levels. Fourteen PIK3CA mutations were identified in exon 9 (6.7 %), and 17 in exon 20 (8.3 %).
PIK3CA mutations, especially in exon 9, were significantly associated with grade I-II tumors. PTEN deletions were detected
in 43 samples (21.50 %) and were significantly associated with grade III tumors (p < 0.001). Univariate analysis showed a
significant association between relapse-free survival (RFS), T and N stage and exon 9 PIK3CA mutations. Overall survival
was significantly associated with T stage, N stage and adjuvant chemotherapy, which was administered to 70.3 % of
patients. In multivariate analyses, T stage, N stage, presence of exon 9 PIK3CA mutations and high EGFR protein level
were independent poor prognostic factors for RFS, while adjuvant chemotherapy was associated with a better outcome.
Conclusions: High EGFR protein expression and exon 9 PIK3CA activating mutations are independent prognostic factors
in TNBC. The efficacy of anti-PI3K targeted therapies needs to be evaluated in this setting.
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Background
Triple negative breast cancers (TNBC) occur most
frequently in young women and tend to have a more
aggressive behavior. They are characterized by a relapse
rate that rapidly rises in the first 2 years after diagnosis,
peaks at 2–3 years post-diagnosis and declines during the
next 5 years [1]. Currently, chemotherapy is the only
systemic therapeutic option for this tumor type because
hormonal therapies and anti-HER2agents are ineffective
due to the lack of expression of these therapeutic targets
in tumor cells.
The transmembrane tyrosine kinase epidermal growth
factor receptor (EGFR), which is encoded by the EGFR
gene located on the short arm of chromosome 7, is
frequently (30–52 %) overexpressed in TNBC [2],
particularly in the basal-like subgroup, and is associated
with poor prognosis [3]. EGFR activation through its
tyrosine kinase domain leads to recruitment of down-
stream effectors and activation of proliferative and cell
survival signaling pathways [4]. In historical reports,
EGFR overexpression, using various detection methods,
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was observed in 14 to 91 % of breast tumors [5]. In
more recent works, EGFR protein expression was
detected in 16 to 36 % of breast cancers [6]. In addition,
EGFR expression is part of the diagnostic criteria used
to identify basal-like TNBC, a TNBC subgroup with worse
prognosis [2]. However, the mechanisms responsible for
EGFR expression in TNBC remain poorly understood.
We previously reported [7], consistently with most of the
published data [8, 9], the absence of EGFR activating
mutations in TNBC samples from Caucasian patients.
Therefore, the putative effect of EGFR TKIs in this
population cannot be linked to activating mutations
but, possibly, to EGFR overexpression or gene ampli-
fication [8–11]. Indeed, other EGFR modifications
have been described in TNBC. Increased EGFR gene
copy number has been inconstantly (0–51 %) reported
in some EGFR-positive breast cancers [4, 8–12]. Cell
membrane EGFR expression was associated with
increased gene copy number in two of these studies
[4, 12], but not with chromosome 7 polysomy in the
report by Burness et al. [4]. Due to the high dispar-
ities in results and methods used for EGFR status
evaluation, a comprehensive analysis of this putative
target in TNBC is required.
The PI3K/PTEN pathway is involved both in EGFR
downstream signaling and in TNBC physiopathology
[13]. Mutations in PIK3CA (the gene encoding the p110
catalytic subunit of PI3K) and PTEN loss of expression
(LOE) have been detected in breast cancers [14]. PTEN
LOE has been observed in 50–82 % of basal-like breast
cancers [15]. PTEN LOE appears to be the main cause
of PI3K pathway alterations in breast cancer and is
strongly associated with hormone receptor positivity
[16], although it is observed also in 8–25 % of TNBC
[11, 17, 18]. Conversely, PIK3CA mutations were detected
in only a small fraction of TNBC with basal-like features
in Martin's study [11]. The high frequency of PTEN LOE
and the low occurrence of PIK3CA mutations in TNBC
with basal-like features might bring support to the still
debated hypothesis of the mutual exclusivity of these two
alterations [14, 15].
Herein, we report the results of the analysis of EGFR
gene amplification, EGFR expression and PIK3CA and
PTEN deletion and their clinicopathological and prog-
nostic implications in a large, comprehensive set of 204
European patients with TNBC.
Methods
Patients and tumor samples
A total of 1695 consecutive patients with breast cancer
referred to the Val d’Aurelle Montpellier Cancer Institute
(ICM) between 2002 and 2010 were prospectively
entered in the database of a dedicated tumor DNA bank
(Biobank number BB-0033-00059). Samples were isolated
from frozen, histologically proven and macro-dissected
invasive breast cancer specimens that were primarily
handled for ER and PR testing by using the dextran
charcoal method, as previously described [19, 20], or for
uPA/PAI-1 quantification with the Femtelle® test. Tumors
were considered as ER and PR positive when the receptor
concentration was higher than 10 fmol/mg of protein
(using the Dextran Charcoal Assay [DCC]), or > 10 %
tumor cells were stained by immunohistochemistry (IHC)
[21]. HER2 status was determined based on HER2 protein
expression level by IHC using the A485 monoclonal anti-
body (Dako, Denmark). Tumors with HER2 scores of 0
and 1+ were considered as HER2 negative. In tumors with
equivocal HER2 IHC test results (2+), gene amplification
was evaluated using fluorescence or chromogenic (CISH)
in situ hybridization. Specimens with HER2 3+ scores
were considered as HER2 positive. Finally, 204 DNA
samples from non-metastatic TNBC were selected for this
study. Each individual treatment proposal was in accord-
ance with our institution guidelines [22]. The clinicopath-
ological characteristics and treatments of the 204 patients
included in this study are summarized in Table 1. This
study was reviewed and approved by the Montpellier
Cancer Institute Institutional Review Board (ID number
ICM-URC-2014/73). All patients gave their written,
informed consent. As part of the study evaluated the
prognostic impact of biological markers, this manuscript
adheres to the REMARK guidelines.
Tissue processing and DNA extraction
DNA was extracted during tumor sample protein extrac-
tion protocol for either ER/PR or uPA PAI quantification.
Briefly, each frozen tumor specimen was pulverized in li-
quid nitrogen and homogenized in a Polytron homogenizer
(Glen Mills, NJ, USA) with a cytosol extraction buffer
(20 mM Tris∙HCI, 1.5 mM ethylenediaminetetraacetic
acid [EDTA], 10 mM Na2MoO4, 1.5 mM dithiothrei-
tol and 10 % glycerol, pH 7.4; in the case of tumors
processed for ER and PR testing using the DCC
assay) or with Triton X-100 buffer (in the case of
tumors processed for uPA/PAI-1 testing using the
Femtelle kit, American Dignostica) with a buffer:tissue
ratio of 10:1 (volume/weight) and centrifuged at 10,000 × g
for 15 min. Total genomic DNA was extracted from
the pellets obtained by centrifugation of either cyto-
sol or Triton extract using the QIAamp DNA extrac-
tion minikit (ref 51304, Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. Superna-
tants were used to prepare cytosol or Triton X-100
protein extracts and the total protein content was
quantified using the Pierce assay (BCA Protein Assay
Kit, Pierce Biotechnology, Rockford, IL) as previously
described [23].
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PIK3CA mutation detection
Polymerase Chain Reaction (PCR) amplification and
High Resolution Melting [24] analysis were performed
on a Rotor-Gene 6000™ instrument (Corbett Research,
Mortlake, New South Wales, Australia) using the Light
Cycler 480 HRM Master MIX kit (Ref 04 909 631 001,
Roche Diagnostics, Meylan, France). Primers were de-
signed to amplify PIK3CA fragments that span the exon
9 hotspot mutation region including the p.E542X and
p.E545X mutations, and the exon 20 region including the
hotspot mutations p.H1047X, p.H1048X and p.G1049X
(Additional file 1: Table S1). Genomic DNA samples from
MCF7 cells (c.1633G >A, p.E545K mutation) and T47D
cells (c.3140 A >G, P.H1047R) were used as positive
controls for PIK3CA exon 9 and exon 20 heterozygous
mutations, respectively. Water (no template) was used to
control for PCR contamination.
After HRM analysis, PCR products were purified using
the ExoSAP-IT kit (ref US78200, GE Healthcare Life
Sciences, Saclay, France) according to the manufacturer's
instructions. Purified PCR products were then used as
templates for sequencing with the Big Dye Terminator
v1.1 kit (Ref 4336774, Applied Biosystems Inc., Foster
City, CA). After migration completion, the PIK3CA
sequences were analyzed with the Applied Biosystems
Sequencing Analysis® software v5.2.
EGFR amplification
Quantitative PCR (qPCR) used in this study was previously
described [25]. Briefly, EGFR copy number was normalized
to beta-actin (ACTB, 7p22.1), a gene located in the
same chromosome, and to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, 2p13.31), a gene located on
another chromosome. We previously used this strategy
[19] to distinguish between real copy number variations
and aneusomy. One DNA sample with amplified EGFR
was used as positive control (EGFR/ACTB ratio = 12.67 ±
2.31) and human placental DNA was used as normal con-
trol (EGFR/ACTB ratio = 0.55 ± 0.06). The theoretical
threshold of gene amplification for a given sample was an
EGFR/ACTB ratio = 2. Below this threshold, the sample
was considered ‘wild type’ and above this threshold, the
sample was considered ‘amplified’.
Detection of PTEN and other chromosome 10 sequence copy
number variations (CNV) by Multiplex Ligation-dependent
Probe Amplification
Multiplex Ligation-Dependent Probe Amplification
(SALSA MLPA probemix P225-D1 PTEN, MRC-Holland,
Amsterdam, the Netherlands) is a high throughput, PCR-
based method to determine the relative copy number of
various human DNA target sequences. The method is
based on the annealing of a mixture of oligonucleotides
(Additional file 2: Table S2) to their cognate DNA
sequences. DNA denaturation, hybridization, ligation,
PCR and fragment analysis were performed according to
the manufacturer’s specification. Raw data were visually
controlled and then normalized using the Coffalyser.Net
software. For each electropherogram, height peaks and
areas under the peaks were exported to Coffalyser.NET.
The algorithm is based on a double normalization (intra-
and inter-sample) and calculates a quotient for each assay
tube. The relative height of each individual probe peak,
compared to the relative probe peak height of various
reference DNA samples, reflects the relative copy number
of the corresponding target sequence in the sample.
Depending on the quotient value, DNA sequences were
considered as normal, with heterozygous duplication, with
Table 1 Patients and tumors’ characteristics
Number of patients (%)
204 100
Age
Median, range 56 29–86
<55 years 98 48.0
























a6 invasive papillary carcinomas, 4 metaplastic carcinomas, 4 undifferentiated
carcinomas, 3 apocrine carcinomas, 3 medullary carcinomas, 3 mixed
ductal-lobular carcinomas, and one/each of the following histological
subtypes: sarcomatoid carcinoma, adenoid cystic carcinoma, adenosquamous
and neuroendocrine carcinoma
NE not evaluated
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heterozygous deletion, with homozygous deletion, or with
non-interpretable results. This approach allows the identi-
fication of PTEN and chromosome 10q loss of heterozy-
gosity (LOH) and aneuploidy.
EGFR protein level
EGFR concentration in cytosol or Triton X-100 protein
extracts was determined using the EGFR ELISA kit
(MERCK ref CBA018), a sandwich enzyme immunoassay
that employs specific goat anti-EGFR polyclonal antibodies.
The range of standardization goes from 31.25 pg/ml to
2000 pg/ml. EGFR levels were standardized to the total
protein content and results expressed in pg/mg of protein
content. Because ranges of EGFR values were different
according to sample preparation, EGFR expression was
divided in terciles, for low, medium and high protein level.
Statistical analysis
Categorical variables were presented as frequency distri-
butions and continuous variables as medians and ranges.
Categorical variables were compared with the Pearson’s
chi-square or Fisher’s exact test. Differences were con-
sidered statistically significant at the p < 0.05 level. Over-
all survival (OS) was calculated from the date of surgery
to the date of death (whatever the cause). Patients lost
to follow-up were censored at the last documented visit.
Relapse-free survival (RFS) was calculated from the
surgery date to the recurrence date. Patients alive at the
last follow-up without recurrence and patients lost to
follow-up were censored at the time of the last follow-
up. Patients who died without recurrence were censored
at the date of death. The Kaplan-Meier method was used
to estimate the OS and RFS rates. Differences in survival
rates were compared using the log–rank test. Statistical
analyses were performed with STATA 13.0 (StatCorp,
College Station, TX).
Results
Patients and Tumor’s characteristics
For this study, 204 DNA samples from TNBC specimens
that included a high percentage (>50 %) of tumor cells,
as required for ER and PR or uPA/PAI-1 testing, were
selected. The main clinicopathological characteristics of
this cohort are summarized in Table 1 and were consistent
with the classical TNBC features (i.e., a majority of T2+
tumors, one third of N+ cancers and high frequency of
high grade tumors, as only nine tumor specimens [4.5 %,
3 ductal carcinomas, 3 ductal carcinomas with tubular
inflexion, 1 lobular carcinoma, 1 invasive papillary carcin-
oma and 1 ductal carcinoma with cribriform inflexion]
were classified as SBR-EE [Elston-Ellis modification of
Scarff-Bloom-Richardson] grade 1). The patients’ median
age was 56 years (range: 29–86 years). Ductal carcinoma
was the most common histological type (79.9 %), 70.3 %
of patients received adjuvant chemotherapy, while the
remaining 29.7 % of patients received adjuvant radiation
therapy if clinically indicated. None of the patients
received additional hormonal therapy, targeted therapy or
an investigational product.
EGFR/PI3K/PTEN pathway alterations and clinicopathological
correlations
The results of the assessment of the EGFR/PI3K/PTEN
axis alterations and of the correlations between EGFR
amplification, EGFR protein level, PIK3CA mutation,
PTEN status and clinicopathological characteristics are
summarized in Table 2. As previously reported [7], no
EGFR-activating mutation was identified in our population.
EGFR amplification was detected in 18 tumor samples
(8.9 %) and was significantly associated with higher EGFR
protein levels compared to TNBC specimens with
normal or deleted EGFR or chromosome 7 polysomy
(p = 0.043, Fig. 1). PIK3CA mutations were identified
in exon 9 (n = 14, 6.7 %) and in exon 20 (n = 17,
8.3 %) (Additional file 3: Table S3). The presence of
PIK3CA mutations was significantly associated with SBR-
EE grade I-II tumors (p = 0.038), particularly in the case of
exon 9 mutations (64.3 % vs. 35.7 %, p = 0.02). PTEN dele-
tions were detected in 43 TNBC specimens (21.5 %) and
were significantly associated with SBR-EE grade III tumors
(p < 0.001). No other statistically significant association
was identified between EGFR/PI3K/PTEN pathway alter-
ations and clinicopathological parameters.
Survival analyses
Using May 1, 2014 as cut-off date, the median follow-up
was 6.4 years (range: 0.1–12.8 years). Forty seven deaths
(5-year OS: 81.3 % [74.8–86.3]) and 52 relapses occurred
(5-year RFS: 76.1 % [69.2–81.6]). The relapse pattern of
our population was consistent with the previously
reported relapse risk temporal distribution [1, 26], as
most relapses occurred during the first 3 years of
follow-up (Additional file 4: Figure S1 and Additional
file 5: Figure S2). Univariate analysis (Table 3) showed
a significant association between RFS and T stage, N
stage and exon 9 PIK3CA mutations and a marginal
association (p = 0.07) with adjuvant chemotherapy. OS
was significantly associated with T stage, N stage, adjuvant
chemotherapy and marginally with exon 9 PIK3CA muta-
tions (p = 0.063) and EGFR status (Polysomy/Amplifica-
tion vs. Deletion/Normal, p = 0.075). As some patients
died from non-TNBC related causes, a multivariate
analysis was performed using RFS data to identify inde-
pendent, TNBC-specific prognostic factors. T stage, N
stage, presence of exon 9 PIK3CA mutations and high
EGFR protein level were identified as independent poor
prognostic factors, while the use of adjuvant chemother-
apy was statistically associated with a better outcome
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Table 2 Correlations between EGFR amplification, EGFR protein level, PIK3CA mutation, PTEN status and clinicopathological characteristics
Patients’ characteristics EGFR gene status EGFR protein level PIK3CA mutations PTEN status
Normal Deletion Amplifi-cation Polysomy p Lower tercile Middle tercile Upper tercile p Exon 9 Exon 20 No p Deletion No deletion p
N % N % N % N % N % N % N % N % N % N % N % N %
Age 0.119 0.412 0.347 0.394
<55 years 76 49.3 6 54.5 11 61.1 5 25.0 31 48.4 27 43.5 35 55.6 5 35.7 6 35.3 87 50.3 23 53.5 72 45.9
≥55 years 78 50.7 5 45.5 7 38.9 15 75.0 33 51.6 35 56.5 28 44.4 9 64.3 11 64.7 86 49.7 20 46.5 85 54.1
T status 0.878 0.836 0.384 0.387
T1 63 40.9 4 36.4 9 50.0 8 40.0 25 39.1 25 40.3 28 44.4 8 57.1 8 47.1 68 39.3 15 34.9 67 42.7
T2+ 91 59.1 7 63.6 9 50.0 12 60.0 39 60.9 37 59.7 35 55.6 6 42.9 9 52.9 105 60.7 28 65.1 90 57.3
N status 0.234 0.182 0.491 0.475
N0 103 66.9 6 54.5 8 44.4 14 70.0 47 73.4 36 58.1 40 63.5 11 78.6 10 58.8 111 64.2 30 69.8 99 63.0
N+ 51 33.1 5 45.5 10 55.6 6 30.0 17 26.6 26 41.9 23 36.5 3 21.4 7 41.2 62 35.8 13 30.2 58 37.0
SBR-EE grade 0.466 0.871 0.038 <0.001
I-II 49 32.5 4 36.4 6 33.3 10 50.0 22 34.9 19 30.7 21 34.4 9 64.3 7 41.2 53 31.2 4 9.8 63 40.4
III 102 67.5 7 63.6 12 66.7 10 50.0 41 65.1 43 69.3 40 65.6 5 35.7 10 58.8 117 68.8 37 90.2 93 59.6
Histology 0.102 0.974 0.103 0.526
Ductal 119 77.3 11 100 17 94.4 15 75.0 50 78.1 50 80.7 50 79.4 12 85.7 10 58.8 141 81.5 36 83.7 123 78.3
Lobular and other 35 22.7 0 0.0 1 5.6 5 5.0 14 21.2 12 19.3 13 20.6 2 14.3 7 41.8 32 18.5 7 16.3 34 21.7
EGFR Gene Status - 0.164 0.873 0.224
Normal 154 100 0 0.0 0 0.0 0 0.0 47 74.6 51 82.3 44 69.8 11 78.6 13 76.4 130 75.6 33 76.8 120 76.9
Deletion 0 0.0 11 100 0 0.0 0 0.0 3 4.8 3 4.8 3 4.8 0 0.0 2 11.8 9 5.2 0 0.0 11 7.0
Amplification 0 0.0 0 0.0 18 100 0 0.0 4 6.3 2 3.2 11 17.5 1 7.1 1 5.9 16 9.3 5 11.6 12 7.8
Polysomy 0 0.0 0 0.0 0 0.0 20 100 9 14.3 6 9.7 5 7.9 2 14.3 1 5.9 17 9.9 5 11.6 13 8.3
EGFR Protein level 0.164 - 0.180 0.110
Lower tercile 47 33.1 3 33.3 4 23.5 9 45.0 64 100 0 0.0 0 0.0 3 27.3 4 26.7 57 35.0 9 21.4 53 36.8
Middle tercile 51 35.9 3 33.3 2 11.8 6 30.0 0 0.0 62 100 0 0.0 7 63.6 4 26.7 51 31.3 14 33.3 47 32.6
Upper tercile 44 31.0 3 33.3 11 64.7 5 25.0 0 0.0 0 0.0 63 100 1 9.1 7 46.6 55 33.7 19 45.3 44 30.6
PIK3CA Mutations 0.873 0.180 - 0.565
Exon 9 11 7.1 0 0.0 1 5.6 2 10.0 3 4.7 7 11.3 1 1.60 14 100 0 0.0 0 0.0 1 2.3 12 7.6
Exon 20 13 8.4 2 18.2 1 5.6 1 5.0 4 6.2 4 6.4 7 11.1 0 0.0 17 100 0 0.0 3 7.0 12 7.6
No 130 84.5 9 81.8 16 88.8 17 85.0 57 89.1 51 82.3 55 87.3 0 0.0 0 0.0 173 100 39 90.7 133 84.8
PTEN Status 0.224 0.110 0.565 -
Deletion 33 21.6 0 0.0 5 29.4 5 27.8 9 14.5 14 23.0 19 30.2 1 7.7 3 20.0 39 22.7 43 100 0 0.0











(Table 4, Fig. 2). These parameters remained significant
independent prognostic factors in the two subgroup
analyses (in the population of tumors excluding the 11
cases with HR values between 1 % and 9 % [n = 193], as
well as in the ductal tumors population [n = 163]).
Discussion
We performed an extensive analysis of the EGFR/
PI3K/PTEN axis alterations and of their clinicopatho-
logical and prognostic implications in a set of 204
European patients with TNBC. The results obtained
in our series are in accordance with comprehensive
evaluations of the mutational spectrum of TNBC re-
ported in the literature [27]. We previously reported
[7] the absence of EGFR-activating mutation in this
series of TNBC. We showed a statistically significant
association between EGFR gene amplification and
EGFR protein expression. As we did not chose to
classify our series of tumors as basal-like or non-
basal-like, but rather to evaluate quantitatively the
level of EGFR protein expression, it appeared that a
quantitative continuous test such as the one offered
by the biochemical assay was the more relevant to
achieve our objective, and thus selected this method
for the EGFR protein evaluation. Our results are con-
sistent with the study by Bhargava et al. [8] who
found a correlation between EGFR gene amplification
(detected in 6 % of their breast cancer patients) and
EGFR overexpression. Interestingly, 73 % of tumors
harboring EGFR gene amplification were TNBC (the
total number of TNBC in this series was not re-
ported). However, they could not differentiate between
chromosome 7 polysomy and true EGFR gene amplifi-
cation, as they used only one EGFR gene probe for
CISH. Two recent reports [11, 28] also found a sig-
nificant correlation between EGFR protein overexpres-
sion (evaluated by IHC) and EGFR gene amplification and
chromosome 7 polysomy by dual probe (EGFR/CEP7)
FISH analysis. However, as concomitant evaluation of the
prognostic value of EGFR gene alterations and EGFR pro-
tein expression (by IHC and biochemically) has never
been reported, it is currently impossible to say which is
the best method(s) to assess EGFR status as a prognostic
indicator in TNBC.
The PI3K pathway is up-regulated in basal-like
cancers and in TNBC. The majority of the reported
mutations is located within the helical (exon 9) and
the kinase (exon 20) domains of the PI3K catalytic
subunit p110 alpha and result in constitutive PI3K
activation, AKT signaling induction and oncogenic
transformation [29]. In our TNBC cohort, exon 9
PIK3CA activating mutations were detected in 6.7 %
and exon 20 mutations in 8.3 % of tumor samples, in
agreement with previously published reports on PIK3CA
mutations in patients with TNBC [14, 30–32]. The
frequency and clinical impact of PIK3CA mutations need
to be assessed in homogeneous biological subgroups of
breast cancers, as the prevalence and biological implica-
tions of these mutations appear to vary in the different
subgroups [13, 14, 31]. Arsenic et al. reported an overall
PIK3CA mutation frequency of 15.8 % in breast cancer
and of 13.2 % in TNBC [30]. Moreover, mutations in exon
20 were more numerous compared with those in exon 9,
in agreement with other works [14, 31] and our results.
Although exon 9 and exon 20 PIK3CA mutations do not
appear to be mutually exclusive and they could have a
synergistic effect [33], they were never concomitantly
detected in our cohort.
Then we showed that exon 9 PIK3CA mutations were
independent prognostic factors in TNBC while exon 20
PIK3CA mutations did not. Previous studies analyzed
PIK3CA mutation prognostic impact in the whole breast
cancer population and not specifically in TNBC [34], or
evaluated together exon 9 and exon 20 PIK3CA muta-
tions [32, 35], or analyzed their prognostic impact in
small series (<100 patients with TNBC) [30, 35]. Inter-
estingly, Zhao et al. [33] showed that PIK3CA muta-
tions in exon 9 and exon 20 could be associated with
different activation mechanisms. Specifically, the gain
of function induced by exon 9 PIK3CA mutations is in-
dependent of binding to the PI3K regulatory subunit
p85, but requires interaction with RAS-GTP. Con-
versely, exon 20 mutants do not require RAS-GTP
binding, but are highly dependent on the interaction
with p85. These molecular differences could, at least
partially, explain the differential prognostic impact of
exon 9 and 20 PIK3CA mutations in our series.
TNBC activation of downstream members of the PI3K
signaling pathway is very common as indicated by the
frequency of PTEN LOE, INPP4B loss and MAGI3 and
AKT3 activating translocations [36]. As we wanted to
Fig. 1 Correlation between EGFR gene status and EGFR protein levels
(blue, lower tercile; red, middle tercile; green, upper tercile)
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Table 3 Univariate analysis
N RFS OS
Events 5-y RFS HR (95 % CI) Events 5-y OS HR (95 % CI)
Age
<55 years 98 21 79.9 1 17 84.1 1
≥55 years 106 31 72.6 1.29 [0.74; 2.24] 30 78.9 1.51 [0.83; 2.73]
p = 0.370 p = 0.174
T
T1 84 11 88.3 1 11 90.7 1
T2+ 120 41 67.5 2.91 [1.50; 5.67] 36 74.7 2.48 [1.26; 4.88]
p = 0.001 p = 0.006
N
N- 132 20 86.9 1 21 89.0 1
N+ 72 32 56.1 3.56 [2.03; 6.22] 26 66.8 2.58 [1.45; 4.59]
p < 0.001 p = 0.001
SBR-EE grade
1-2 69 17 79.9 1 15 86.3 1
3 132 35 73.7 1.13 [0.63; 2.02] 32 78.4 1.21 [0.65; 2.24]
p = 0.676 p = 0.541
Histology
Ductal 163 42 75.4 1 40 80.0 1
Lobular/Other 41 10 78.7 0.93 [0.47; 1.86] 7 86.6 0.67 [0.30; 1.49]
p = 0.848 p = 0.325
Adjuvant CT
No 60 21 66.7 1 24 69.1 1
Yes 142 31 80.1 0.60 [0.35; 1.05] 23 86.8 0.40 [0.23; 0.71]
p = 0.070 p = 0.001
EGFR status
Normal/Deletion 165 41 78.0 1 35 81.8 1
Ampl./Polysomy 38 11 65.9 1.36 [0.69; 2.65] 12 78.5 1.80 [0.93; 3.49]
p = 0.368 p = 0.075
PIK3CA status
No mutation 173 40 78.0 1 36 83.2 1
Exon 9 14 7 61.5 2.62 [1.17; 5.86] 7 69.2 2.55 [1.13; 5.74]
Exon 20 17 5 67.8 1.38 [0.54; 3.50] 4 70.5 1.23 [0.44; 3.46]
p = 0.048 p = 0.063
EGFR protein level
Lower and middle tercile 126 30 79.4 1 27 84.1 1
Upper tercile 63 20 66.0 1.54 [0.87; 2.72] 17 73.8 1.42 [0.78; 2.62]
p = 0.131 p = 0.247
PTEN status
No deletion 157 38 78.5 1 33 83.4 1
Deletion 43 13 67.7 1.38 [0.74; 2.60] 13 75.1 1.66 [0.87; 3.16]
p = 0.309 p = 0.117
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evaluate the most stable PTEN modifications, we con-
sidered that genomic alterations were the most relevant
way to identify stable PTEN loss of function. Thus, the
evaluation of PTEN deletions using the MLPA methods
appeared the most robust way to identify a true PTEN
deficiency in our population. PTEN deletions were de-
tected in 21.50 % and were significantly associated with
grade III tumors (p < 0.001). PIK3CA mutations and
PTEN loss are considered to be nearly mutually exclusive
in breast tumors [11, 14], a characteristic shared by our
series, as only four tumors presented concomitantly a
PTEN deletion and a PIK3CA activating mutation (one in
exon 9, three in exon 20, Table 2). PTEN dysregulation,
observed in 16.6 to 63 % of TNBC depending on the
evaluation method and the disease stage [17, 35, 37, 38],
has been consistently reported to be associated with poor
prognosis in these patients [37, 38]. The lack of significant
association between PTEN deletion and RFS/OS in our
study could be linked to the fact that we evaluated exclu-
sively PTEN deletions, rather than PTEN LOE, and the
frequency of PTEN abnormalities (20.1 %) was thus lower
than in classical LOE studies [17, 35, 37, 38]. An extensive
evaluation of the different mechanisms responsible for
PTEN LOE, together with PTEN expression by IHC,
could be useful for understanding its clinical and bio-
logical implications in our population.
A potential pitfall of our study could be linked to
the choice of a European definition of TNBC, consid-
ering a <10 % negativity threshold for the determin-
ation of the hormone receptor status. However, the
fact that the exclusion of the 11 cases with HR values
between 1 and 9 % did not change the multivariate
analysis results, and the fact that recent biological studies
showed a close biologic similarity between the <1 % HR
and 1–9 % HR population [39], both strengthen our
results.
Conclusions
High EGFR protein expression and exon 9 PIK3CA
activating mutations are independent prognostic factors in
TNBC. These different molecular abnormalities could
affect TNBC sensitivity to various anticancer treatments
under development, such as mTOR inhibitors, PARP in-
hibitors or androgen receptor inhibitors. Therefore, it is
now important to globally evaluate the EGFR/PI3K/PTEN
pathway, together with androgen receptor and DNA
repair deficiency status, to better identify different TNBC
subgroups that could be sensitive to various kinase inhibi-
tors, including anti-PI3K targeted therapies, or specific
targeted therapy combinations.
Table 4 Multivariate analysis (RFS)
HR 95 % CI p
T 0.008
T1 1
T2+ 2.48 [1.21; 5.07]
N <0.001
N- 1
N+ 4.17 [2.23; 7.78]
Adjuvant CT 0.003
No 1
Yes 0.39 [0.22; 0.70]
PIK3CA Exon 9 Mutation 0.001
No 1
Yes 6.38 [2.42; 16.8]
EGFR protein level 0.011
Lower and middle tercile 1
Upper tercile 2.22 [1.22; 4.03]
Fig. 2 Relapse-Free Survival rates in patients with TNBC (n = 204) in function of time according to a PIK3CA mutations, b EGFR protein
levels (terciles)
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